Australian (ASX) Stock Market Forum

IVG - Invert Graphite

Jump to new
S

Snakey

Joined
8 November 2006
Posts
469
Reactions
1
I been watching this company for a few years but have never traded it. Today this company announced - World Wide Exclusive Laboratory Supply Contract signed. It is currently trading at .58 with market cap of 11.7 mil.
This company was the first in the world to culture stem cells. Up 20% today on ann.
 
Re: TIS - Tissue Therapies

This biotech company's main product is VitroGro for treating burns and skin treatments (see attached AGM presentation on http://www.tissuetherapies.com/). They have an impressive list of patents in place.

Today they announced an agreement that will result in the world-wide distribution of VitroGro for use by biomedical scientists in research institutions and pharmaceutical and biotech companies.
 
Re: TIS - Tissue Therapies

Ferrets Stock to Watch: TISSUE THERAPIES LTD
08:50, Wednesday, 31 January 2007

LOCAL BIOTECH COMPANY SIGNS WORLD-WIDE PROTEIN PLATFORM

Sydney - Wednesday - January 31: (RWE Aust Business News)
*********************************************************

OVERVIEW
********

Tissue Therapies Ltd (ASX:TIS) has joined with the strength by
signing a world-wide exclusive agreement with Invitrogen Corporation.

It is a provider of essential life science technologies for
disease research and drug discovery for the promotion and sale of
VitroGro.

The product is used in live cell research for the production of
proteins and development of new health treatments.

Tissue Therapies's agreement will result in the world-wide
distribution of the synthetic VitroGro protein platform.

It will be used by biomedical scientists in research
institutions and pharmaceutical and biotechnology companies, who need,
or prefer to use, a completely synthetic, defined media for the growth
of cells and production of proteins.

Invitrogen Corporation is headquartered in Carlsbad, California,
and provides products and services that support academic and government
research institutions, as well as pharmaceutical and biotechnology
companies.

Products are sold directly in most major countries and through
distributors or agents in all others.

In 2007 the company is celebrating 20 years of accelerating
scientific discovery, including advancements in stem cell and chemically
defined media.

The VitroGro protein platform that will be sold world wide by
Invitrogen will be manufactured to Good Manufacturing Practice (GMP)
standard.

This will substantially simplify experimental work on future
health and medical therapies developed or tested with live cells by
making regulatory approval for these treatments simpler, faster and less
expensive.

CEO Dr Steven Mercer said, "This is an exciting day for Tissue
Therapies.

"We are delighted to have formalised a world-wide sales and
distribution agreement for GMP VitroGro with Invitrogen, one of the most
sophisticated, innovative and well respected life science companies in
the world.

"We could not wish for a better partner to promote VitroGro to
pharmaceutical and biotechnology companies, as well as academic and
government research institutions."

Joydeep Goswami, Vice President, Stem Cells and Regenerative
Medicine at Invitrogen said he believes VitroGro could provide an
excellent animal-origin free substrate for feeder-free culture of stem
cells.

"It is a natural fit with our efforts to provide a broad
portfolio of serum-free and defined products for stem cell culture to
stem cell researchers around the globe," Mr Goswami declared.

The demand for completely synthetic, defined media for biologic
research is expanding rapidly.

"There are many practical and technical advantages to biomedical
scientists in using cell growth media that contain only known,
characterised, synthetic proteins, particularly when the media is made to
GMP standards."

Dr Mercer explained, "To the best of our knowledge, the VitroGro
media to be sold by Invitrogen is the only completely synthetic, defined,
cell media available in the world today in which human stem cells can be
grown.

"This gives us a significant competitive advantage, particularly
when it is also made to GMP standards," he added.

Under the agreement, Tissue Therapies will supply VitroGro
manufactured under contract, at an agreed supply price to Invitrogen.

Additional Tissue Therapies revenue will be generated by
half-yearly royalty payments as well as additional one-time payments on
the achievement of agreed milestones.

Sales are expected to start early in the second half of calendar
2007.

SHARE PRICE MOVEMENTS
*********************

Shares of Tissue Therapies rose 12c to 60.5c on Monday and
touched 72c after the agreement news, but slipped half a cent to 60c
yesterday. Rolling high for the year is 72c and low 35c. The company has
20 million shares on issue while the market cap is $12.2 million.

Research into the core cell replication, protein synthesis and
migration technologies will continue to build on the basic VitroGro
intellectual property.

Technical founders and key research team from the Queensland
University of Technology (QUT) are:

* Consulting chief scientific officer Professor Zee Upton.
Under an agreement with QUT, Professor Upton is consulting Chief
Scientific Officer and head of the research team at QUT.

She brings significant expertise in growth factor protein,
molecular and cellular technologies to the project, including the
recombinant production of proteins.

* Dr Shooter is a Research Fellow within the Tissue
Bioregeneration and Integration program at QUT.

* Dr David Leavesley brings cellular and molecular research
technology expertise to the project.

The commercialisation and licensing team comprises Dr Mercer, who
brings considerable international expertise to Tissue Therapies following
a successful career with multinational companies; Chief Operating Officer
Nigel Johnson, who was recruited from the Australian Red Cross Blood
Service (ARCBS) where he was responsible for operational and regulatory
activities at the ARCBS Skin Bank; and Administrative Officer Abrona
Chappell, who joined Tissue Therapies in September 2004 to conduct the
company's administrative and co-ordination activities.

BACKGROUND
**********

Tissue Therapies Ltd was listed on the Australian Stock Exchange
on March 19, 2004.

The company was incorporated in 2002 to commercialise Tissue
Culture and Repair technology from the Queensland University of
Technology (QUT) in Brisbane.

It is an Australian company developing biomedical technologies
for wound healing, tissue and various cell culture applications.

The company has worldwide exclusive rights to commercialise
VitroGro, a platform technology developed by tissue engineering experts
at the Institute for Health and Biomedical Innovation at QUT for
enhancing cell growth and migration.

VitroGro has particular commercial applications in wound
healing, tissue regeneration, stem cell therapies and other cell culture
uses.

Based on its VitroGro platform technology, Tissue Therapies is
developing more effective medical treatments for wounds and burns,
integration of orthopaedic and medical implants, and other applications
such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance
the growth of mammalian cells for emerging cell-based therapies, along
with research and industrial cell culture markets internationally.

Invitrogen Corporation provides products and services that
support academic and government research institutions and pharmaceutical
and biotech companies worldwide in their efforts to improve the human
condition.

The company provides essential life science technologies for
disease research, drug discovery, and commercial bioproduction.

Invitrogen's own research and development efforts are focused on
breakthrough innovation in all major areas of biological discovery
including functional genomics, proteomics, bioinformatics and cell
biology - placing Invitrogen's products in nearly every major laboratory
in the world.

Invitrogen globally employs about 5,000 scientists and other
professionals and had revenues of more than $1.2 billion in 2006.

ENDS

Copyright © 2007 RWE Australian Business News. All rights reserved.
 
TIS - Tissue Therapies Limited

TIS is a biotechnology company that provides wound healing, tissue repair and cell culture technology through a growth factor platform technology VitroGro ®

Despite announcing today a $695,600 loss for the year (which was previously targetted) this stock has a Strong Buy recommendation from Aegis equities and also received coverage this morning from RWE Australian Business news as follows:

Tissue Therapies (TIS) - Buy; Price Target: 71c; Share Price: 56c; Market Cap: $11m.

TIS has signed a supply contract with Invitrogen Corporation (Nasdaq: IVGN) for the promotion and sale of VitroGro.

This agreement will result in the world-wide distribution of TIS's VitroGro protein platform for use by biomedical scientists in research institutions and pharmaceutical and biotech companies.

Few terms of the agreement have been released. Under the agreement TIS will supply VitroGro (manufactured under contract) at an agreed supply price to Invitrogen.

Additional revenue will be generated by half-yearly royalty payments as well as additional one-time payments on the achievement of agreed milestones.

Sales are expected to start early in 2HCY07. We view this as very positive news for TIS and in line with the company's milestone table.


Recently TIS announced:

World Wide Exclusive Laboratory Supply Contract Signed

Biomedical company, Tissue Therapies Limited (ASX: TIS) has achieved a major business development milestone by signing a world wide exclusive agreement with Invitrogen Corporation (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery, for the promotion and sale of VitroGro ®. VitroGro ® is used in live cell research for the production of proteins and development of new health treatments.

This agreement will result in the world wide distribution of the synthetic VitroGro ® protein platform for use by biomedical scientists in research institutions and pharmaceutical and biotechnology companies, who need, or prefer to use, a completely synthetic, defined media for the growth of cells and production of proteins.

Headquartered in Carlsbad, California, Invitrogen provides products and services that support academic and government research institutions, as well as pharmaceutical and biotechnology companies. Products are sold directly in most major countries and through distributors or agents in all others. In 2007, the company is celebrating 20 years of accelerating scientific discovery, including advancements in stem cell and chemically defined media.

The VitroGro ® protein platform that will be sold world wide by Invitrogen will be manufactured to Good Manufacturing Practice (GMP) standard. This will substantially simplify experimental work on future health and medical therapies developed or tested with live cells by making regulatory approval for these treatments simpler, faster and less expensive.

For what it's worth - I presently hold this stock.
 
Re: TIS - Tissue Therapies

It looks like the movement may have started towards the target of 71c. Up 8.6% today to 63c.
 

Attachments

  • tis.gif
    tis.gif
    7.6 KB · Views: 280
Re: TIS - Tissue Therapies

Rights issue this week for TIS with 1 share for every 3 held at a buy price of 50c.

Funds are intended to be used for:

assist in manufacturing components for vitrogro
human clinical trials of vitrogro
continue business development activities re licensing
fund vitrogro R&D
strengthen IP position

This looks pretty sound and seems to be a good offer for existing shareholders.

Record date for holdings is March 8th so you may have a chance at getting in before then.
 
Re: TIS - Tissue Therapies

So that you are not on your own here, BCF, let me join in: can anyone explain why, before trading today, 2 March, there were no buys (and only 6 sells) listed on this stock? As market open approached, one single buy at around 40 appeared, later to be modified to 51.

Is this bizarre behaviour - or am I missing something? Any explanation?

BTW 28 Feb was not the best date to announce the new rights issue, but I guess they weren't to know that.
 
Re: TIS - Tissue Therapies

YAY! Someone else is interested.

I had a sell order in prior to this anomoly and I got a message from my platform that said it was PURGED. The same thing happened with BLT which also did a prospectus and rights issue.

It was funny watching market depth go to nil on each side on both stocks. This is good in my opinion as it lets us get a fresh look at who really wants to trade rather than speculative buy/sell sitting there just in case they get a go.

Yes the rights issue was unfortunately timed but for all we know it may have been good that it happened as it could have held the stock up through the crap.
 
Re: TIS - Tissue Therapies

Gurgler said:
So that you are not on your own here, BCF, let me join in: can anyone explain why, before trading today, 2 March, there were no buys (and only 6 sells) listed on this stock? As market open approached, one single buy at around 40 appeared, later to be modified to 51.

Is this bizarre behaviour - or am I missing something? Any explanation?

BTW 28 Feb was not the best date to announce the new rights issue, but I guess they weren't to know that.
Click to expand...

The stock went Ex for the rights issue on 2 March. Basically, from that date anybody buying the shares was not entitled to the rights issue.
On the day that a stock goes Ex for a rights issue, the ASX purges all orders in both the buy and sell.
 
Re: TIS - Tissue Therapies

BCF and Dubio

Thanks for the feedback.

Currently lanquishing at 51. Lets see if the South African ann creates any interest.
 
Re: TIS - Tissue Therapies

I had my doubts with the 50c rights issue. But this is on the move again. Minimal buy depth though so things could change pretty quickly. I think this is worth a 6-12 month stint at current prices.
 
Re: TIS - Tissue Therapies

BCF

I'd appreciate you opinion - at what price does the rights issue become viable: 60/70/80c?
I take your point about volume. There's not much action atm.
 
Re: TIS - Tissue Therapies

I'm not sure I understand the question?? The record date has passed. For those that were in at the time there's now the chance to get 1 at 50c for every 3 held. I haven't received any paperwork for it yet though....

The SP is above 50c at present - how much it can stay above is the interesting question and I think this is what you meant. i.e. if it maintains above 60c then I'd gladly take up the 50c offer. The stock was tipped to go to 71c (Price Target from news release in my trading platform). It was comfortable at 60odd cents but the Shanghai thing and the rights issue has pulled it down.

Unless a great announcement comes out I don't see that this is going anywhere beyond 60c until the share purchase plan thing passes.
 
Re: TIS - Tissue Therapies

Thanks, you answered my poorly expressed question. Yes, I heard 71 as a target also and wondered upon what that was based. I was in when the rights issue was offered but unsure whether to follow through. I believe the paperwork is being sent today - due in sometime next week.

It's just recovered to my purchase price :eek: . I originally thought of it as longer term, but am having doubts.
 
Re: TIS - Tissue Therapies

Gurgler said:
I originally thought of it as longer term, but am having doubts.
Click to expand...

I think a longer term view is the way to go with this one. Plodding along, doing their thing and taking on valuable partners.

See Announcement today "Joint Development signed with Novozymes".
 
Re: TIS - Tissue Therapies

Ferret's Stock to Watch: TISSUE THERAPIES LTD
08:58, Monday, 19 March 2007

BIOTECH COMPANY SIGNS UP ANOTHER IMPORTANT JOINT VENTURE

Sydney - Monday - March 19: (RWE Aust Business News)
****************************************************

OVERVIEW
********

Shareholders of Tissue Therapies Ltd (ASX:TIS) should be
disappointed by the market response to the latest deal involving its
research technology product VitroGro.

The shares have slipped on the week, goodness knows why when one
broker who knows the company well has given Tissue a much better price.

Last week Tissue Therapies reported a joint development deal with
Novozymes A/S for the development of advanced wound dressing products
combining proprietary Novozymes technologies with Tissue Therapies's
VitroGro technology.

Headquartered in Denmark, Novozymes is a respected world leader
in enzymes and other biological protein production and innovation ,with
sales in 2006 of more than $A1.5 billion and a market capitalisation of
around $A7 billion.

Scott Power, senior biotech researcher for ABN AMRO, has given
Tissue Therapies a buy recommendation and a price target of 71c with a
fair value figure of 95c.

Mr Power suggests the latest joint development is a strong
validation of the company's technology.

He says the the collaboration will involve one of Novozymes's
scientist moving to Brisbane to work with Tissue Therapies.

Technologies from both companies will be used to treat a range of
wounds, particularly the acceleration of wound healing.

Commercial outcomes of the collaboration may emerge over the
longer term and at this stage the company is making no changes to
forecasts.

In February, Tissue Therapies reported that the South African
Patent Office had advised that the VitroGro patent Growth Factor
Complexes and Modulation of Cell Migration and Growth had been granted
and the Deed of Letters Patent have been received by Tissue Therapies.

The acceptance of this patent in South Africa fulfills another
step in the international rollout of the VitroGro patent applications
also lodged by Tissue Therapies in the US, Canada, Europe, Australia, New
Zealand, South Korea, China, Hong Kong, India and Japan.

The granting of the patent in South Africa follows the earlier
acceptance of core VitroGro patent in Australia and New Zealand.

SHARE PRICE MOVEMENTS
*********************

Shares of Tissue Therapies rose 2c to 54c on Friday. Rolling high
for the year is 69c and low 33.5c. The all-time high is $1.06. The
company has been 20.2 million shares on issue with a market cap of $10.9
million.

At the annual meeting last November chairman Roger Clarke told
shareholders that the company's commercialisation programs have
positioned it superbly to launch into both clinical trial work and sales
into the live cell laboratory market during 2007.

The innovative and commercially important goals of procuring
VitroGro components to Good Manufacturing Practice (GMP) standard for
human use at a fraction of the current world market price, as well as
successfully developing freeze dried VitroGro, have built a solid
foundation for the commercial success of Tissue Therapies in its target
markets.

"At the same time we have maintained a prudent financial position
and a modest cash burn rate," Mr Clarke said.

"We continue to deliver against all our major, announced
milestones.

"This has positioned the company very well for strong future
growth and is a tribute to the hard work of the entire company.

"On your behalf, I would especially like to thank Professor Zee
Upton and her team and Dr Steven Mercer for the progress made and for
positioning the company for an exciting future, Mr Clarke told
shareholders.

In January this year Tissue Therapies signed a world wide
exclusive agreement with Invitrogen Corporation.

It is a provider of essential life science technologies for
disease research and drug discovery, and for the promotion and sale of
VitroGro.

The product is used in live cell research for the production of
proteins and development of new health treatments.

Tissue Therapies's agreement will result in the worldwide
distribution of the synthetic VitroGro protein platform.

It will be used by biomedical scientists in research institutions
and pharmaceutical and biotechnology companies who need, or prefer to
use, a completely synthetic, defined media for the growth of cells and
production of proteins.

Invitrogen is headquartered in Carlsbad, California, and provides
products and services that support academic and government research
institutions, as well as pharmaceutical and biotechnology companies.

Products are sold directly in most major countries and through
distributors or agents in all others.

In 2007, the company is celebrating 20 years of accelerating
scientific discovery, including advancements in stem cell and chemically
defined media.

The VitroGro protein platform that will be sold worldwide by
Invitrogen will be manufactured to GMP standard.

CEO Dr Steven Mercer said the agreement with Invitrogen is an
exciting step for Tissue Therapies.

"We are delighted to have formalised a worldwide sales and
distribution agreement for GMP VitroGro with Invitrogen, one of the most
sophisticated, innovative and well respected life science companies in
the world," he said.

BACKGROUND
**********

Tissue Therapies Ltd was listed on the Australian Stock Exchange
on March 19, 2004.

The company was incorporated in 2002 to commercialise Tissue
Culture and Repair technology from the Queensland University of
Technology (QUT) in Brisbane.

It is an Australian company developing biomedical technologies
for wound healing, tissue and various cell culture applications.

The company has worldwide exclusive rights to commercialise
VitroGro, a platform technology developed by tissue engineering experts
at the Institute for Health and Biomedical Innovation at QUT for
enhancing cell growth and migration.

VitroGro has particular commercial applications in wound healing,
tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro platform technology, Tissue Therapies is
developing more effective medical treatments for wounds and burns,
integration of orthopaedic and medical implants, and other applications
such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance
the growth of mammalian cells for emerging cell-based therapies, along
with research and industrial cell culture markets internationally.

Invitrogen provides products and services that support academic
and government research institutions and pharmaceutical and biotech
companies worldwide in their efforts to improve the human condition.

The company provides essential life science technologies for
disease research, drug discovery, and commercial bioproduction.

Invitrogen's own research and development efforts are focused on
breakthrough innovation in all major areas of biological discovery
including functional genomics, proteomics, bioinformatics and cell
biology - placing Invitrogen's products in nearly every major laboratory
in the world.

Invitrogen globally employs about 5,000 scientists and other
professionals and had revenues of more than $1.2 billion in 2006.
 
Re: TIS - Tissue Therapies

spottygoose said:
Ferret's Stock to Watch: TISSUE THERAPIES LTD
08:58, Monday, 19 March 2007

BIOTECH COMPANY SIGNS UP ANOTHER IMPORTANT JOINT VENTURE

Sydney - Monday - March 19: (RWE Aust Business News)
****************************************************
Click to expand...

Es-Gee:
there seem to be a few small-lot buyers who are reflecting a slow appreciation of this stock. I'll watch the progress with interest.
 
Re: TIS - Tissue Therapies

Gurgler said:
Es-Gee:
there seem to be a few small-lot buyers who are reflecting a slow appreciation of this stock. I'll watch the progress with interest.
Click to expand...

There has been some real interest today. As someone else noted there has been NO post SPP sell-off which was a very positive sign. Buyers have been building this morning and sellers drying up fast.

Mind you there might be some profit takers from the SPP come out of the woodwork now we have hit 60c again but looks like TIS might be on the way back to the $1 mark now that they have some good partnerships.
 
Re: TIS - Tissue Therapies

SP jumped in three stages today - to .53 at 11.30, then to .55 at 13.40 and finally to .58 at 14.50 (volume 260,400 only). Now .59, I notice.

Wonder if someone is in "the know":eek:
 
Top